1. Home
  2. XMAX vs GYRE Comparison

XMAX vs GYRE Comparison

Compare XMAX & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XMAX Inc. Common Stock

XMAX

XMAX Inc. Common Stock

N/A

Current Price

$8.98

Market Cap

529.8M

ML Signal

N/A

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$6.86

Market Cap

606.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XMAX
GYRE
Founded
N/A
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
529.8M
606.4M
IPO Year
2009
2004

Fundamental Metrics

Financial Performance
Metric
XMAX
GYRE
Price
$8.98
$6.86
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$17.00
AVG Volume (30 Days)
574.0K
47.4K
Earning Date
N/A
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
88.51
N/A
EPS
0.62
N/A
Revenue
$12,744,871.00
$275,000.00
Revenue This Year
N/A
$19.88
Revenue Next Year
N/A
N/A
P/E Ratio
$13.89
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.10
$5.44
52 Week High
$9.40
$9.42

Technical Indicators

Market Signals
Indicator
XMAX
GYRE
Relative Strength Index (RSI) 54.87 53.40
Support Level $8.33 $5.67
Resistance Level $9.34 $8.28
Average True Range (ATR) 0.26 0.32
MACD -0.04 0.04
Stochastic Oscillator 51.41 49.58

Price Performance

Historical Comparison
XMAX
GYRE

About XMAX XMAX Inc. Common Stock

XMax Inc is a designer and lifestyle furniture company. The company is a designer and distributor of contemporary styled residential and commercial furniture. The firms marketing and sales platform offers retail as well as online selection and purchase fulfillment internationally. The company also sells managed a variety of bedding foundation components. Its collection of lifestyle furniture brands includes Diamond Sofa. The firm's products are made in the United States and Asia. The company plans expansion into artificial intelligence (AI) while continuing to operate and develop its existing furniture business.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: